The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational anti-integrin therapies
- Med Res Rev. 2020 Jan;40(1):245-262. doi: 10.1002/med.21601.
Affiliations
- 1. Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- 2. Department of Gastroenterology, Hôpital Saint-Louis, AP-HP, INSERM U1160, University Denis Diderot, Paris, France.
- 3. Gastrointestinal Immunopathology Laboratory and IBD Unit, Humanitas Clinical and Research Center, Milan, Italy.
- 4. Department of Research and Early Development, Genentech, South San Francisco, California.
- 5. Department of Product Development, Genentech, South San Francisco, California.
PMID: 31215680
DOI: 10.1002/med.21601
Abstract
Inflammatory bowel disease (IBD) is characterized by uncontrolled inflammation in the gastrointestinal tract. The underlying pathobiology of IBD includes an increase in infiltrating gut-homing lymphocytes. Although lymphocyte homing is typically a tightly regulated and stepwise process involving multiple integrins and adhesion molecules expressed on endothelial cells, the distinct roles of integrin-expressing immune cells is not fully understood in the pathology of IBD. In this review, we detail the involvement of integrins expressed on specific lymphocyte subsets in the pathogenesis of IBD and discuss the current status of approved and investigational integrin-targeted therapies.
Keywords
Crohn's disease, ulcerative colitis; anti-integrin therapy; inflammatory bowel disease; integrins.